Chronic naltrexone differentially affects supraspinal δ-opioid receptor-mediated antinociception

European Journal of Pharmacology

Volumn 345, Issue 1, 1998, Pages 47-53

  Kest, Benjamin ^a   Lee, Cynthia E ^a   Jenab, Shirzad ^a   Kao, Bernard ^a   Inturrisi, Charles E ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Opioid receptor; Morphine; Naltrexone; Naltriben; Supersensitivity; Up regulation

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DELTORPHIN; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; LEVALLORPHAN; MORPHINE; NALTREXONE; NALTRIBEN; PLACEBO; RECEPTOR SUBTYPE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LIGAND BINDING; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUPERSENSITIVITY; TAIL FLICK TEST;

ANALGESICS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; REACTION TIME; RECEPTORS, OPIOID, DELTA; SPINAL CORD; UP-REGULATION;

EID: 0032510589     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01584-7     Document Type: Article

References (38)

1. Abdelhamid E.E., Sultana M., Portoghese P.S., Takemori A.E. Selective blockage of δ opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 258:1991;299-303.
2. 2-opioid receptor agonists. Eur. J. Pharmacol. 311:1996;127-132.
3. Belcheva M.M., Barg J., Mchale R., Coscia C.J. Naltrexone induces down- and up-regulation of δ-opioid receptors in rat brain regions. Brain Res. Bull. 35:1994;69-72.
4. Buzas B., Izenwasser S., Portoghese P.S., Cox B.M. Evidence for δ opioid receptor subtypes regulating adenylyl cyclase activity in the rat brain. Life Sci. 54:1994;101-106.
5. 3 opiate receptor binding in the mouse and rat. Eur. J. Pharmacol. 226:1992;15-20.
6. Corbett A.D., Gillan M.G.C., Kosterlitz H.W., McKnight A.T., Paterson S.J., Robson L.E. Selectivities of opioid peptide analogues as agonists and antagonists at the δ-receptor. Br. J. Pharmacol. 83:1984;271-279.
7. Duttaroy A., Billings B., Candido J., Yoburn B.C. Chronic D-amphetamine inhibits opioid receptor antagonist-induced supersensitivity. Eur. J. Pharmacol. 221:1992;211-215.
8. Erspamer V., Melchiorri P., Falconieri-Erspamer G., Negri L., Corsi R., Severini C., Barra D., Simmaco M., Kreil G. Deltorphins: A family of naturally occurring peptides with high affinity and selectivity for δ-opioid binding sites. Proc. Natl. Acad. Sci. USA. 86:1989;5188-5192.
9. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
10. Jenab S., Kest B., Inturrisi C.E. Assessment of δ opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment. Br. Res. 691:1995;69-75.
11. 2]Deltorphin II, a highly selective δ-agonist in vivo. Life Sci. 47:1990;PL43-PL47.
12. 6]Enkephalin and naltrindole 5′-isothiocyanate: Evidence for δ receptor subtypes. J. Pharmacol. Exp. Ther. 257:1991;1069-1075.
13. 2-opioid receptors. Life Sci. 55:1994;121-126.
14. Kest B., Lee C.E., McLemore G.M., Inturrisi C.E. An antisense oligodeoxynucleotide for the δ opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence. Brain Res. Bull. 39:1996;185-188.
15. Kest B., Lee C.E., Mogil J.S., Inturrisi C.E. Blockade of morphine supersensitivity by an antisense oligodeoxynucleotide targeting a δ opioid receptor (DOR-1). Life Sci. 60:1997;PL155-PL159.
16. 2-agonist antinociception. Neuroreport. 5:1994;1049-1052.
17. Lowry O.H., Rosebrough A.L., Farr J., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
18. 2]deltorphin II in mice: Evidence for δ receptor subtypes. J. Pharmacol. Exp. Ther. 258:1991;583-587.
19. Mattia A., Farmer S.C., Takemori A.E., Sultana M., Portoghese P.S., Mosberg H.I., Bowen W.D., Porreca F. Spinal opioid δ antinociception in the mouse: Mediation by a 5′-NTII-sensitive δ receptor subtype. J. Pharmacol. Exp. Ther. 260:1992;518-525.
20. 2 opioid receptors in the development of morphine dependence in mice. J. Pharmacol. Exp. Ther. 264:1993;1141-1145.
21. Morris B.J., Millan M.J., Herz A. Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of μ, δ, and κ binding sites in rat brain revealed by quantitative autoradiography. J. Pharmacol. Exp. Ther. 247:1988;729-736.
22. Mosberg H.I., Hurst R., Hruby V.J., Gee K., Yamamura H.I., Galligan J.J., Burks T.F. Bis-penicillamine enkephalins possess highly improved specificity toward δ-opioid receptors. Proc. Natl. Acad. Sci. USA. 80:1983;5871-5874.
23. 2-receptors. J. Pharmacol. Exp. Ther. 263:1992;147-152.
24. 5]enkephalin, in the μ-opioid receptor deficient CXBK mouse. Eur. J. Pharmacol. 216:1992;453-456.
25. i3 transducer proteins. Life Sci. 53:1993;PL129-PL134.
26. Shah S., Davis T., Yoburn B.C. The effect of naltrindole on spinal and supraspinal δ opioid receptors and analgesia. Life Sci. 55:1994;1451-1458.
27. Sofuoglu M., Portoghese P.S., Takemori A.E. Differential antagonism of δ opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for δ opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257:1991;676-680.
28. Standifer K.M., Chien C.-C., Wahlestedt C., Brown G.P., Pasternak G.W. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ-opioid receptor. Neuron. 12:1994;805-810.
29. Suh H.H., Tseng L.F. Different types of opiate receptors mediating analgesia induced by morphine, DAMGO, DPDPE, DADLE, and β-endorphin in mice. Naunyn-Schmiedebergs Arch. Pharmacol. 342:1990;67-71.
30. Takemori A.E., Portoghese P.S. Evidence for the interaction of morphine with κ and δ opioid receptors to induce analgesia in β-funaltrexamine-treated mice. J. Pharmacol. Exp. Ther. 243:1987;91-104.
31. Takemori A.E., Sultana M., Nagase H., Portoghese P.S. Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone. Life Sci. 50:1992;1491-1495.
32. Tempel A., Gardner E.L., Zukin R.S. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J. Pharmacol. Exp. Ther. 232:1985;439-444.
33. Umans J.G., Inturrisi C.E. Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine, and morphine in mice. J. Pharmacol. Exp. Ther. 218:1981;409-415.
34. Yoburn B.C., Inturrisi C.E. Modification of the response to opioid and nonopioid drugs by chronic opioid antagonist treatment. Life Sci. 42:1988;1689-1696.
35. Yoburn B.C., Luke M.C., Pasternak G.W., Inturrisi C.E. Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci. 43:1988;1319-1324.
36. Yoburn B.C., Paul D., Azimuddin S., Lutfy K., Sierra V. Chronic opioid antagonist treatment increases μ and δ receptor mediated spinal opioid analgesia. Brain Res. 485:1989;176-178.
37. Yoburn B.C., Sierra V., Lutfy K. Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation. Brain Res. 529:1990;143-148.
38. Zukin R.S., Sugarman J.R., Fitz-Syage M.L., Gardner E.L., Zukin S.R., Gintzler A.R. Naltrexone-induced opiate receptor supersensitivity. Brain Res. 245:1982;285-292.